主页 > 医药生命 >
【商业翻译—医师报约稿】Magnesium Sulfate More Ef
2.本星期六（7.7）22：00前交稿。
3.翻译并非简单直译，格式见版内置顶的文摘编译格式：
http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准。
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领。
6.每位战友最多认领2篇。
7.作者统一署名为"丁香"。
8.文中出现的杂志名称用原文，无需翻译。
Magnesium Sulfate More Effective Than Nifedipine in Preventing Preterm Delivery
News Author: Laurie Barclay, MD
CME Author: Penny Murata, MD
Disclosures
Release Date: June 29, 2007; Valid for credit through June 29, 2008
June 29, 2007 — Magnesium sulfate is more effective than nifedipine in preventing preterm delivery for 48 hours, but nifedipine is linked with fewer maternal adverse events, according to the results of a randomized controlled trial published in the July issue of Obstetrics & Gynecology.
"Magnesium sulfate is the most commonly used first-line tocolytic in North America although it has not been demonstrated to be superior to saline infusion, and its use has been a source of controversy," write Deirdre J. Lyell, MD, from Stanford University Medical Center and Lucile S. Packard Children's Hospital in California, and colleagues. "Magnesium sulfate requires intravenous administration, has potential for overmedication with serious maternal adverse effects and may be associated with adverse neonatal effects.... Nifedipine may be more easily tolerated, is administered orally, and appears to have few adverse effects."
The objective of this multicenter randomized study was to compare the efficacy and adverse effects of intravenous magnesium with those of oral nifedipine for acute tocolysis of preterm labor in 192 patients in active preterm labor who were at 24 to 33 weeks and 6 days of gestation. The main endpoint was arrest of preterm labor, defined as prevention of delivery for 48 hours with uterine quiescence.
Compared with women treated with nifedipine, more women treated with magnesium sulfate achieved the main endpoint (87% vs 72%; P = .01). Both groups were similar in delivery within 48 hours (7.6% magnesium sulfate vs 8.0% nifedipine; P = .92), gestational age at delivery (35.8 vs 36.0 weeks; P = .61), birth before 37 and 32 weeks (57% vs 57%; P = .97 and 11% vs 8%; P = .39, respectively), and episodes of recurrent preterm labor.
In the magnesium sulfate group, mild and severe maternal adverse effects were significantly more frequent than in the nifedipine group. Although average birth weight, birth weight less than 2500 g, and neonatal morbidities were similar in both groups, newborns of mothers in the magnesium sulfate group spent longer in the neonatal intensive care unit (8.8 ± 17.7 vs 4.2 ± 8.2 days; P = .007).
Study limitations include lack of double-blinding or placebo control and failure to establish the optimal doses of magnesium sulfate and nifedipine.
"Patients who received magnesium sulfate achieved the primary outcome more frequently," the authors write. "However, delay of delivery, gestational age at delivery, and neonatal outcomes were similar between groups. Nifedipine was associated with fewer maternal adverse effects."
The Division of Maternal–Fetal Medicine at Stanford University and the Department of Obstetrics and Gynecology at Santa Clara Valley Medical Center supported this study. The authors have disclosed no relevant financial relationships.
Obstet Gynecol. 2007;110:61-67. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 楼上的兄弟, 动手了么?
本人认领了. 3小时内提交译文. Magnesium Sulfate More Effective Than Nifedipine in Preventing Preterm Delivery
硫酸镁比硝苯地平预防早产更为有效
News Author: Laurie Barclay, MD
CME Author: Penny Murata, MD
Disclosures
Release Date: June 29, 2007; Valid for credit through June 29, 2008
June 29, 2007 — Magnesium sulfate is more effective than nifedipine in preventing preterm delivery for 48 hours, but nifedipine is linked with fewer maternal adverse events, according to the results of a randomized controlled trial published in the July issue of Obstetrics & Gynecology.
2007年6月29日-硫酸镁预防48小时早产效果优于硝苯地平，而硝苯地平引起产妇不良反应较少。这一随机对照试验的研究结果刊登在七月号妇产科杂志。
"Magnesium sulfate is the most commonly used first-line tocolytic in North America although it has not been demonstrated to be superior to saline infusion, and its use has been a source of controversy," write Deirdre J. Lyell, MD, from Stanford University Medical Center and Lucile S. Packard Children's Hospital in California, and colleagues. "Magnesium sulfate requires intravenous administration, has potential for overmedication with serious maternal adverse effects and may be associated with adverse neonatal effects.... Nifedipine may be more easily tolerated, is administered orally, and appears to have few adverse effects."
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-16 17:11
医学,生命科学网